Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
Endocrine

17-09-2024 | Type 2 Diabetes | Review Free for a limited time

The possible effect of anti-diabetic agents GLP-1RA and SGLT-2i on the respiratory system function

Authors: Kanella Kantreva, Paraskevi Katsaounou, Katerina Saltiki, Georgia Trakada, Georgia Ntali, Theodora Stratigou, Marinella Tzanela, Theodora Psaltopoulou, Stavroula A. Paschou

Published in: Endocrine

Login to get access

Abstract

Type 2 Diabetes (T2D) is a chronic disease with increasing incidence and prevalence and serious chronic complications, especially from cardiovascular system. However, other organs can be affected too. Several studies have associated T2D, especially when poorly controlled, with multiple pulmonary diseases. T2D is a common comorbidity among patients with asthma, Chronic Obstructive Pulmonary Disease (COPD), and Obstructive Sleep Apnea Syndrome (OSAS), and it is related to higher respiratory infection incidence, prevalence and severity. Glucagon-like peptide-1 receptor agonists (GLP-1RA) and Sodium-glucose co-transporter-2 inhibitors (SGLT-2i) are novel antihyperglycaemic agents with established cardiovascular benefits. There are also limited studies indicating their potential benefit in respiratory function. The aim of this article is to review data on the impact of GLP-1RA and SGLT-2i on respiratory function and describe the possible clinical benefits. Key findings indicate that GLP-1RA significantly improve lung function in patients with COPD, evidenced by improvements in spirometry measurements. Additionally, both GLP-1RA and SGLT-2i are associated with a decreased risk of severe and moderate exacerbations in COPD patients and have shown potential in reducing the incidence of respiratory disorders, including asthma and pneumonia. The mechanisms underlying these benefits are not yet fully understood and include multiple effects, such as anti-inflammatory action and oxidative stress reduction.
Literature
1.
2.
K.L. Ong, L.K. Stafford, S.A. McLaughlin, E.J. Boyko, S.E. Vollset, A.E. Smith et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402, 203–234 (2023)CrossRef
3.
4.
M.R. Schuyler, D.E. Niewoehner, S.R. Inkley, R. Kohn. Abnormal lung elasticity in juvenile diabetes mellitus. Am Rev. Respir. Dis. 113, 37-41 (1976).
5.
S.A. Paschou, E. Bletsa, K. Saltiki, P. Kazakou, K. Kantreva, P. Katsaounou. et al. Sleep Apnea and Cardiovascular Risk in Patients with Prediabetes and Type 2 Diabetes. Nutrients. 14, 4989 (2022)
6.
S.F. Ehrlich, C.P. Quesenberry, S.K. Van Den Eeden, J. Shan, A. Ferrara, Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care 33, 55–60 (2010)CrossRefPubMed
7.
T. Enomoto, J. Usuki, A. Azuma, T. Nakagawa, S. Kudoh, Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis. Chest. 123, 2007–2011 (2003)CrossRefPubMed
8.
Wang D., Ma Y., Tong X., Zhang Y., Fan H. Diabetes Mellitus Contributes to Idiopathic Pulmonary Fibrosis: A Review From Clinical Appearance to Possible Pathogenesis. Front. Public Health. 8, 196 (20200).
9.
C. Hyldgaard, O. Hilberg, E. Bendstrup, How does comorbidity influence survival in idiopathic pulmonary fibrosis? Respir. Med. 108, 647–653 (2014)CrossRefPubMed
10.
J.B. Kornum, R.W. Thomsen, A. Riis, H.H. Lervang, H.C. Schønheyder, H.T. Sørensen, Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care 31, 1541–1545 (2008)CrossRefPubMedPubMedCentral
11.
A. Al-Sayyar, K.D. Hulme, R. Thibaut, J. Bayry, F.J. Sheedy, K.R. Short. et al. Respiratory tract infections in diabetes – lessons from tuberculosis and influenza to guide understanding of COVID-19 severity. Front. Endocrinol. 13, 91923 (2022).
12.
S.J. McGurnaghan, A. Weir, J. Bishop, S. Kennedy, L.A.K. Blackbourn, D.A. McAllister et al. Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes Endocrinol. 9, 82–93 (2021)CrossRefPubMed
13.
H. Zheng, J. Wu, Z. Jin, L.J. Yan. Potential biochemical mechanisms of lung injury in diabetes. Aging Dis. 8, 7 (2017).
14.
S. Singh, Y.S. Prakash, A. Linneberg, A. Agrawal, Insulin and the lung: connecting asthma and metabolic syndrome. J. Allergy 2013, 1–8 (2013)CrossRef
15.
L. Zhang, f. Jiang, Y. Xie, Y. Mo, X. Zhang, C. Liu. Diabetic endothelial microangiopathy and pulmonary dysfunction. Front. Endocrinol. 14, 1073878 (2023).
16.
L. Fuso, D. Pitocco, A. Longobardi, F. Zaccardi, C. Contu, C. Pozzuto et al. Reduced respiratory muscle strength and endurance in type 2 diabetes mellitus. Diabetes Metab. Res. Rev. 28, 370–375 (2012)CrossRefPubMed
17.
S.A. Meo. Significance of spirometry in diabetic patients. Int. J. Diabetes Mellit. 2, 47–50 (2010).
18.
A. Aparna. Pulmonary function tests in type 2 diabetics and non-diabetic people - A comparative study. J. Clin. Diagnos. Res. 7, 1606–1608 (2013)
19.
S. Mittal, M. Mittal, M. Jindal, S. Srivastava, S. Sinha. Evaluation of pulmonary functions in patients with type 2 diabetes mellitus: a cross-sectional study. Cureus 15, 3–4 (2023).
20.
O.L. Klein, J.A. Krishnan, S. Glick, L.J. Smith. Systematic review of the association between lung function and Type 2 diabetes mellitus. Diabetic Med. 27, 977–987 (2010).
21.
W. Jiao. 1 AIC, LMG-MMER, LX. Causal associations of sleep apnea and snoring with type 2 diabetes and glycemic traits and the role of BMI. Obesity. 31, 652−664 (2023)
22.
23.
24.
R. Nevola, R. Epifani, S. Imbriani, G. Tortorella, C. Aprea, R. Galiero et al. GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives. Int. J. Mol. Sci. 24, 1703 (2023)
25.
E.D. Michos, G.L. Bakris, H.W. Rodbard, K.R. Tuttle. Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection. Am. J. Prev. Cardiol. 14, 10052 (2023)
26.
M. Grieco, A. Giorgi, M.C. Gentile, M. d’Erme, S. Morano, B. Maras et al. Glucagon-Like Peptide-1: a focus on neurodegenerative diseases. Front. Neurosci. 13, 1112 (2019)
27.
H. Yaribeygi, M. Maleki, T. Jamialahmadi, S.A. Moallem, A. Sahebkar. Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders. EXCLI J. 22, 403–414 (2023)
28.
A. Pawlos, M. Broncel, E. Woźniak, P. Gorzelak-Pabiś. Neuroprotective effect of SGLT2 inhibitors. Molecules. 23, 7213 2021.
29.
J. Nespoux, V. Vallon. Renal effects of SGLT2 inhibitors: an update. Curr. Opin. Nephrol. Hypertens. 29, 190–198 (2020)
30.
W. Widiarti, A.C. Sukmajaya, D. Nugraha, F.F. Alkaff. Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: a systematic review. Diabetes Metab. Syndr. Clin. Res. Rev. 15, 837–843 (2021)
31.
C. de Graaf, D. Donnelly, D. Wootten, J. Lau, P.M. Sexton, L.J. Miller et al. Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes. Pharmacol. Rev 68, 954–1013 (2016)CrossRefPubMedPubMedCentral
32.
M. Körner, M. Stöckli, B. Waser, J.C. Reubi, GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J. Nuclear Med. 48, 736–743 (2007)CrossRef
33.
C.O. Mendivil, H. Koziel, J.D. Brain. Metabolic hormones, apolipoproteins, adipokines, and cytokines in the alveolar lining fluid of healthy adults: compartmentalization and physiological correlates. PLoS ONE. 10, e0123344 (2015)
34.
D.V. Nguyen, A. Linderholm, A. Haczku, N. Kenyon. Glucagon-like peptide 1: A potential anti-inflammatory pathway in obesity-related asthma. Pharmacol. Ther.180, 139–143 (2017).
35.
A.D. Altintas Dogan, O. Hilberg, S. Hess, T.T. Jensen, E.M. Bladbjerg, C.B. Juhl, Respiratory effects of treatment with a glucagon-like Peptide-1 receptor agonist in patients suffering from obesity and chronic obstructive pulmonary disease. Int. J. COPD 17, 405–414 (2022)CrossRef
36.
R. Pradhan, S. Lu, H. Yin, O.H.Y. Yu, P. Ernst, S. Suissa et al. Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: Population based cohort study. BMJ 379, 8–10 (2022)
37.
Y. Albogami, K. Cusi, M.J. Daniels, Y.J.J. Wei, A.G. Winterstein, Glucagon-like peptide 1 receptor agonists and chronic lower respiratory disease exacerbations among patients with type 2 diabetes. Diabetes Care 44, 1344–1352 (2021)CrossRefPubMedPubMedCentral
38.
P. Rogliani, M.G. Matera, L. Calzetta, N.A. Hanania, C. Page, I. Rossi et al. Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. Respir. Med. 154, 86–92 (2019)CrossRefPubMed
39.
J.P. Wei, C.L. Yang, W.H. Leng, L.L. Ding, G.H. Zhao, Use of GLP1RAs and occurrence of respiratory disorders: a meta-analysis of large randomized trials of GLP1RAs. Clin. Respir. J. 15, 847–850 (2021)CrossRefPubMed
40.
M. Yu, R. Wang, L. Pei, X. Zhang, J. Wei, Y. Wen et al. The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials. Diabetol. Metab. Syndr. 15, 164 (2023).
41.
A. Chaudhuri, H. Ghanim, M. Vora, C.L. Sia, K. Korzeniewski, S. Dhindsa et al. Exenatide exerts a potent antiinflammatory effect. J. Clin. Endocrinol. Metab. 97, 198–207 (2012)CrossRefPubMed
42.
G. Bendotti, L. Montefusco, M.E. Lunati, V. Usuelli, I. Pastore, E. Lazzaroni et al. The anti-inflammatory and immunological properties of GLP-1 receptor agonists. Pharmacol. Res. 182, 106320 (2022)CrossRefPubMed
43.
W. Zhou, W. Shao, Y. Zhang, D. Liu, M. Liu, T. Jin, Glucagon-like peptide-1 receptor mediates the beneficial effect of liraglutide in an acute lung injury mouse model involving the thioredoxin-interacting protein. Am. J. Physiol. Endocrinol. Metab. 319, E568–E578 (2020)CrossRefPubMedPubMedCentral
44.
P.D. Mitchell, B.M. Salter, J.P. Oliveria, A. El-Gammal, D. Tworek, S.G. Smith et al. Glucagon-like peptide-1 receptor expression on human eosinophils and its regulation of eosinophil activation. Clin. Exp. Allergy 47, 331–338 (2017)CrossRefPubMed
45.
T. Zhu, X.L. Wu, W. Zhang, M. Xiao, Glucagon like peptide-1 (GLP-1) modulates OVA-induced airway inflammation and mucus secretion involving a protein kinase A (PKA)-dependent nuclear factor-κB (NF-κB) signaling pathway in mice. Int. J. Mol. Sci. 16, 20195–20211 (2015)CrossRefPubMedPubMedCentral
46.
S. Gou, T. Zhu, W. Wang, M. Xiao, X.C. Wang, Z.H. Chen, Glucagon like peptide-1 attenuates bleomycin-induced pulmonary fibrosis, involving the inactivation of NF-κB in mice. Int. Immunopharmacol. 22, 498–504 (2014)CrossRefPubMed
47.
B. Baer, N.D. Putz, K. Riedmann, S. Gonski, J. Lin, L.B. Ware et al. Liraglutide pretreatment attenuates sepsis-induced acute lung injury. Am. J. Physiol. Lung Cell Mol. Physiol 325, L368–L384 (2023)CrossRefPubMedPubMedCentral
48.
W. Yue, F. Dang, X. Zang, Y. Du, X. Fan, H. Su, T. Pan. Dulaglutide provides protection against sepsis-induced lung injury in mice by inhibiting inflammation and apoptosis. Eur J Pharmacol. 949, 175730 (2023)
49.
E. Vara, J. Arias-Díaz, C. Garcia, L. Balibrea, E. Blázquez. Glucagon-like Peptide-1(7-36) Amide Stimulates Surfactant Secretion in Human Type II Pneumocytes [Internet]. Am. J. Respir. Crit. Care. Med. (2001). Available from: www.​atsjournals.​org
50.
H.P. Haagsman, R.V. Diemel. Surfactant-associated proteins: functions and structural variation. Compar. Biochem. Physiol. Part A. 129, 91−108 (2001)
51.
J. Fandiño, L. Toba, L.C. González-Matías, Y. Diz-Chaves, F. Mallo. GLP-1 receptor agonist ameliorates experimental lung fibrosis. Sci. Rep. 10, 18091 (2020)
52.
T. Zhu, Li C., X. Zhang, C. Ye, S. Tang, W. Zhang et al. GLP-1 analogue liraglutide enhances SP-A expression in LPS-induced acute lung injury through the TTF-1 signaling pathway. Mediat. Inflamm. 2018, 3601454 (2018)
53.
C. López-Cano, A. Ciudin, E. Sánchez, F.J. Tinahones, F. Barbé, M. Dalmases et al. Liraglutide improves forced vital capacity in individuals with Type 2 diabetes: data from the randomized crossover LIRALUNG Study. Diabetes. 71, 315–320 (2022)CrossRefPubMed
54.
N.E. Viby, M.S. Isidor, K.B. Buggeskov, S.S. Poulsen, J.B. Hansen, H. Kissow, Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice. Endocrinology. 154, 4503–4511 (2013)CrossRefPubMed
55.
P. Rogliani, L. Calzetta, B. Capuani, F. Facciolo, M. Cazzola, D. Lauro et al. Glucagon-like peptide 1 receptor: a novel pharmacological target for treating human bronchial hyperresponsiveness. Am. J. Respir. Cell Mol. Biol. 55, 804–814 (2016)CrossRefPubMed
56.
T., Sato, T. Shimizu, H. Fujita, Y. Imai, D.J. Drucker, Y. Seino et al. GLP-1 receptor signaling differentially modifies the outcomes of sterile vs viral pulmonary inflammation in male mice. Endocrinology. 161, bqaa201 (2020)
57.
Dixon A.E., Peters U. The effect of obesity on lung function. Expert. Rev. Respir. Med. Taylor and Francis Ltd.; 2018. 755–767
58.
W. Jiang, W. Li, J. Cheng, W. Li, F. Cheng, Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea. Sleep Breathing 27, 1687–1694 (2023)CrossRefPubMed
59.
Cliona O’Donnell SCAOBOMTRGKMMLDODJMJDDSR. Continuous Positive Airway Pressure but Not GLP1-mediated Weight Loss Improves Early Cardiovascular Disease in Obstructive Sleep Apnea: A Randomized Proof-of-Concept Study
60.
J.I. Fonseca-Correa, R. Correa-Rotter. Sodium-Glucose Cotransporter 2 inhibitors mechanisms of action: a review. Front. Med. 8, 777861 (2021)
61.
N.A. Elsayed, G. Aleppo, V.R. Aroda, R.R. Bannuru, F.M. Brown, D. Bruemmer et al. 9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2023. Diabetes Care 46, S140–S157 (2023)CrossRefPubMed
62.
M. Qiu, L.L. Ding, Z.L. Zhan, S.Y. Liu, Use of SGLT2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of SGLT2 inhibitors. Endocrine. 73, 31–36 (2021)CrossRefPubMed
63.
D.G. Yin, M. Qiu, X.Y. Duan. Association between SGLT2is and cardiovascular and respiratory diseases: a meta-analysis of large trials. Front. Pharmacol. 12, 724405 (2021)
64.
P.C.M. Au, K.C.B. Tan, D.C.L. Lam, B.M.Y. Cheung, I.C.K. Wong, W.C. Kwok et al. Association of sodium-glucose cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 inhibitor use with risk of incident obstructive airway disease and exacerbation events among patients with type 2 Diabetes in Hong Kong. JAMA Netw. Open 6, e2251177 (2023)CrossRefPubMedPubMedCentral
65.
H.E. Jeong, S. Park, Y. Noh, S. Bea, K.B. Filion, O.H.Y. Yu et al. Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study. BMC Med. 21, 47 (2023)
66.
K. Sawada, S. Karashima, M. Kometani, R. Oka, Y. Takeda, T. Sawamura et al. Effect of sodium glucose cotransporter 2 inhibitors on obstructive sleep apnea in patients with type 2 diabetes. Endocr. J. 65, 461−467 (2018)
67.
L. Xie, S. Li, X. Yu, Q. Wei, F. Yu, J. Tong. DAHOS Study: Efficacy of dapagliflozin in treating heart failure with reduced ejection fraction and obstructive sleep apnea syndrome - A 3-month,multicenter, randomized controlled clinical trial. Eur. J. Clin. Pharmacol. 80, 771–780 (2024)CrossRefPubMed
68.
M.N. Kosiborod, R. Esterline, R.H.M. Furtado, J. Oscarsson, S.B. Gasparyan, G.G. Koch et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 9, 586–594 (2021)CrossRefPubMedPubMedCentral
69.
F. Lin, C. Song, Y. Zeng, Y. Li, H. Li, B. Liu et al. Canagliflozin alleviates LPS-induced acute lung injury by modulating alveolar macrophage polarization. Int. Immunopharmacol. 88, 106969 (2020)
70.
E.E. Abd El-Fattah, S. Saber, A.A.E. Mourad, E. El-Ahwany, N.A. Amin, S. Cavalu et al. The dynamic interplay between AMPK/NFκB signaling and NLRP3 is a new therapeutic target in inflammation: emerging role of dapagliflozin in overcoming lipopolysaccharide-mediated lung injury. Biomed. Pharmacother. 147, 112628 (2022)
71.
D. Huang, F. Ju, L. Du, T. Liu, Y. Zuo, G.W. Abbott et al. Empagliflozin protects against pulmonary ischemia/reperfusion injury via an extracellular signal-regulated kinases 1 and 2-dependent mechanism. J. Pharmacol. Exp. Ther. 380, 230–241 (2022)CrossRefPubMed
72.
A.M. Kabel, R.S. Estfanous, M.M. Alrobaian. Targeting oxidative stress, proinflammatory cytokines, apoptosis and toll like receptor 4 by empagliflozin to ameliorate bleomycin-induced lung fibrosis. Respir. Physiol. Neurobiol. 273, 103316 (2020)
73.
E.H. Baker, D.L. Baines. Airway glucose homeostasis: a new target in the prevention and treatment of pulmonary infection. Chest. 153, 507–514 (2018)
74.
A. Åstrand, C. Wingren, A. Benjamin, J.S. Tregoning, J.P. Garnett, H. Groves et al. Dapagliflozin-lowered blood glucose reduces respiratory Pseudomonas aeruginosa infection in diabetic mice. Br. J. Pharmacol. 174, 836–847 (2017)CrossRefPubMedPubMedCentral
75.
B. Chowdhury, A.Z. Luu, V.Z. Luu, M.G. Kabir, Y. Pan, H. Teoh et al. The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension. Biochem. Biophys. Res. Commun. 524, 50–56 (2020)CrossRefPubMed
Metadata
Title
The possible effect of anti-diabetic agents GLP-1RA and SGLT-2i on the respiratory system function
Authors
Kanella Kantreva
Paraskevi Katsaounou
Katerina Saltiki
Georgia Trakada
Georgia Ntali
Theodora Stratigou
Marinella Tzanela
Theodora Psaltopoulou
Stavroula A. Paschou
Publication date
17-09-2024

EASD 2024

‘Noninferior’ reduction of type 1 diabetes HbA1c by weekly insulin efsitora alfa

Weekly treatment with insulin efsitora is noninferior to daily insulin degludec for the reduction of HbA1c in adults with type 1 diabetes, show the findings of the QWINT-5 trial.

Read more

Weight loss with new obesity drug amycretin

Tirzepatide significantly reduces UACR in individuals with obesity and type 2 diabetes

Liraglutide reduces BMI for young children with obesity

» View more highlights on the EASD 2024 hub page

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits